VENTOLIN

Drug GlaxoSmithKline, LLC.
Total Payments
$1.2M
Transactions
224
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $1.1M 204 0
2023 $73,556 6 0
2022 $24,234 7 0
2020 $6,248 5 0
2019 $3,315 2 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.2M 224 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL GlaxoSmithKline, LLC. $1.1M 0
207661 GlaxoSmithKline, LLC. $38,489 0
0000000000000000000000000000000000000000000000000000000000000000213289 GlaxoSmithKline, LLC. $30,710 0
208071 GlaxoSmithKline, LLC. $25,089 0
0000000000000000000000000000000000000000000000000000000000000000208071 GlaxoSmithKline, LLC. $24,234 0

Top Doctors Receiving Payments for VENTOLIN

Doctor Specialty Location Total Records
Unknown New York, NY $1.2M 224

About VENTOLIN

VENTOLIN is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 224 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..

Payment data is available from 2019 to 2024. In 2024, $1.1M was paid across 204 transactions to 0 doctors.

The most common payment nature for VENTOLIN is "Unspecified" ($1.2M, 100.0% of total).

VENTOLIN is associated with 5 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL" ($1.1M).